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SUMMARY 
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Embryogenesis requires epigenetic information that allows each cell to respond appropriately to 
developmental cues. Histone modifications are core components of a cell’s epigenome, giving rise to 
chromatin states that modulate genome function. Here, we systematically profile histone modifications 
in a diverse panel of mouse tissues at 8 developmental stages from 10.5 days post conception until 
birth, performing a total of 1,128 ChIP-seq assays across 72 distinct tissue-stages. We combine these 
histone modification profiles into a unified set of chromatin state annotations, and track their activity 
across developmental time and space. Through integrative analysis we identify dynamic enhancers, 
reveal key transcriptional regulators, and characterize the role of chromatin-based repression in 
developmental gene regulation. We also leverage these data to link enhancers to putative target genes, 
revealing connections between coding and non-coding sequence variation in disease etiology. Our 
study provides a compendium of resources for biomedical researchers, and achieves the most 
comprehensive view of embryonic chromatin states to date. 
 
MAIN TEXT 
 
 Embryonic development relies on a complex interplay between genetic and epigenetic factors. 
While genetic information encoded in DNA sequence provides the instructions for an embryo to 
develop, epigenetic information is required for each cell type in an embryo to obtain its specialized 
function from a single set of instructions. More specifically, the functional output of a given DNA 
sequence depends on its chromatin state, which is defined in large part by posttranslational 
modifications of histone proteins1,2. These histone modifications take many forms, and they can 
influence gene expression by directly modulating DNA-histone interactions, or serving as binding sites 
for cognate reader proteins that function downstream to enhance or repress transcription3. Importantly, 
histone modifications allow for the transmission of gene activity states through cell division4, which is 
crucial for the maintenance of cellular identity. Given the importance of histone modifications in gene 
regulation, it is not surprising that mutations in genes that encode histones or histone modifying 
enzymes can lead to a wide variety of diseases including cancer, neurodevelopmental disorders, and 
congenital malformations5-7. 
 Histone modifications have also proven to be valuable markers for genome annotation8,9. 
Different types of functional sequences have distinct patterns of histone modifications, which can be 
profiled using Chromatin Immunoprecipitation sequencing (ChIP-seq). For example, chromatin around 
active promoters is characterized by H3K4me3 and H3K27ac, while chromatin around active enhancers 
is often marked by H3K4me1 and H3K27ac10-12. While the profiles of individual histone modifications 
can be informative, the most comprehensive functional annotations are achieved when multiple histone 
modifications are integrated into a unified set of chromatin states based on combinatorial patterns13-15. 
Each region in the genome can then be classified according to its chromatin state, providing insight into 
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its potential function.  
 
Profiling of histone modifications across developmental time and tissues 
 
 Despite the importance of chromatin states in determining the functional output of the genome, 
a comprehensive survey of chromatin states during mammalian embryonic development has been 
lacking. The mouse is an ideal system to study the developmental epigenome because it is the most 
widely used animal model in biomedical research, and offers experimental access to early stages of 
embryonic development. We harvested mouse tissues at closely spaced intervals from 10.5 days post 
conception (E10.5) until birth, which is roughly equivalent to gestational week 3 of human development 
through the end of the first trimester of pregnancy. At each stage, we dissected a diverse panel of 
tissues from multiple litters of C57BL/6N embryos and performed 2 replicates of ChIP-seq for each of 8 
histone modifications (H3K4me1, H3K4me2, H3Kme3, H3K27ac, H3K27me3, H3K9ac, H3K9me3, 
H3K36me3) (Figure 1a-b; Extended data figure 1). These include all six “core” histone modifications 
required by the International Human Epigenome Consortium (IHEC) to generate a reference 
epigenome16,17. At the earliest stage sampled (E10.5) it was not feasible to harvest enough tissue for 
standard ChIP-seq, so we used a modified micro-ChIP-seq procedure designed to work on much 
smaller numbers of cells and restricted our scope to only these 6 histone modifications. The complete 
data series includes more than 66 billion sequencing reads from 564 ChIP-seq experiments, each 
consisting of two biological replicates derived from different embryo pools (N=1,128 replicates total). All 
datasets were generated according to ENCODE standards and processed with a standardized pipeline 
that only outputs peaks passing strict reproducibility criteria18 (see Methods; Extended data figure 2a). 
In total, we identified more than 45 million peaks covering roughly one-third of the mouse genome 
(Extended data figure 2b-d).  
 We observed several high-level features of the data series that warrant comment here. First, as 
expected, the landscape of histone modifications is highly variable between tissues, particularly for 
marks of activity such H3K27ac and H3K9ac (Figures 1c, 2a; Extended data figure 3d). We observe 
that tissues with closer developmental origins tend to have similar histone modification profiles. For 
example, tissues of the Central Nervous System (CNS) can be easily distinguished from other tissues 
by hierarchical or k-means clustering (Figures 2a-b), as well as by principle component analysis 
(Extended data figure 2e). In addition to differences between tissues, histone modification profiles 
change progressively within each tissue during development (Figures 1d, 2c-d, Extended data figure 3). 
These developmental dynamics likely reflect at least two underlying biological processes: 1) changes in 
the epigenetic landscape of individual cells within a tissue as they undergo differentiation, and 2) shifts 
in the relative abundance of different cell types that compose a tissue. Although we cannot separate the 
contributions of these two factors, many of the epigenetic changes we observe reflect known hallmarks 
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of cellular differentiation. For example, we observe a dramatic shift in activity from Myh7 to Myh6 in 
heart at P0, which is known to occur in cardiomyocytes just prior to birth19 (Figure 1d). In the developing 
forebrain, we observe that markers of mature neurons such as NeuroD2 and Gad1 acquire active 
histone modifications during development, and concomitantly lose repressive modifications20,21 (Figure 
1d; Extended data figure 3a). We observe the opposite trend at genes encoding key cell cycle factors 
such as Ccnb1 and Cdk2, where active histone modifications decrease during forebrain development 
as neurons mature and exit the cell cycle (Extended data figure 3b-c). As a general trend, we observe 
that regions of histone modification restricted in developmental time or space are more likely to be 
distal to Transcriptional Start Sites (TSS; Extended data figure 3d). This is consistent with the model 
that TSS-distal regulatory elements play a key role in determining cellular identity22,23. 
 
An integrated 15-state model characterizes the developmental chromatin landscape 
 
 To leverage the information captured by combinatorial patterns of histone modifications (i.e. 
chromatin states) we applied ChromHMM13 to the data series, excluding E10.5 because this stage did 
not have the full complement of histone modification profiles. We first determined the optimal number of 
chromatin states to describe the data (Figure 3a, Extended data figure 4a-c, and Methods). Multiple 
approaches converged on a 15-state model, which shows near-perfect consistency between biological 
replicates, and is in general agreement with previously published models developed from partially 
overlapping sets of histone modifications13,16,24 (Extended data figure 4d-g). Although our chromatin 
state designations were made without considering gene locations, the distribution of each state relative 
to genes matches expectations25 (Figure 3b). We grouped the resulting chromatin states into 4 broad 
functional classes: promoter states, enhancer states, transcriptional states, and heterochromatic states. 
It is important to note that these chromatin state annotations are specific to this study, and are distinct 
from the ENCODE Consortium’s candidate regulatory element registry and Encyclopedia (ENCODE 
Consortium, in preparation). In total, we find that ~33.4% of the genome shows a chromatin signature 
characteristic of one of these four functional classes (i.e. excluding state 15 “no signal”, and state 11 
“permissive”) in at least one tissue or developmental stage. This does not necessarily mean that 33.4% 
of the genome sequence is functional, but rather that 33.4% of the genome sequence is packaged in 
chromatin that shows a reproducible signature in at least one of the tissues or stages profiled here. 
These chromatin signatures reflect transcriptional and/or regulatory activity, but the sequences they 
mark may not be functional by strict definition. For example, the transcriptional elongation state (state 
#10) covers the introns of many highly transcribed genes, but much of the sequence in these introns 
may not contribute to the fitness of the organism.  
 The chromatin state maps provide powerful tools for genome annotation, as a broad range of 
inferred functional information can be visualized across multiple tissues and stages in a single genome 
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browser view (Figure 3c-e; Extended data figure 5a-b). For example, we see that active chromatin 
states robustly and specifically mark master regulators of tissue development including Gata4 and 
Nkx2-5 in heart26, Nkx2-1 in lung27, Cdx2 in intestine28, Barx1 in stomach29, and Wt1 in kidney30. While 
examining chromatin state maps at these genes that code for tissue-restricted transcription factors 
(TFs), we noted that they are frequently marked by a heterochromatic state characteristic of Polycomb-
mediated repression (state 13, Hc - Polycomb associated) outside of their tissues of activity. Polycomb-
mediated repression is known to be essential for embryogenesis31-33, but the genomic distribution of 
repressive chromatin during mammalian development has not been thoroughly examined. To further 
investigate the role of Polycomb-mediated repression in development, we used GREAT34 to examine 
Gene Ontology (GO) terms associated with regions of Polycomb repressive chromatin. We found that 
Polycomb repressive chromatin is highly enriched near TF genes in every tissue and stage surveyed 
here (Figure 4a). Moreover, TF genes that are underlie human Mendelian diseases35 are particularly 
likely to be marked by repressive chromatin (Figure 4b), suggesting that these genes are tightly 
regulated by a combination of repression and activation. We also examined a small but well-
characterized set of genes (Sox9, Pax3, Shh, Ihh, and Wnt6) that are known to cause human 
congenital phenotypes when ectopically expressed during development36-38. Notably, every one of 
these genes is widely marked by repressive chromatin in tissues where they are not active (Figure 4b; 
Extended data figure 5c). These data support an essential and pervasive role for Polycomb-mediated 
repression in silencing key developmental regulators outside of their normal expression domains, which 
may function in turn to control broader programs of gene expression39. We note that the 
heterochromatic state characterized by H3K9me3 (state #14, Hc - H3K9me3) and likely representative 
of facultative heterochromatin shows a very different distribution, as previously described40-44 (Extended 
data figure 6). 
 The breadth of data collected here allowed us to globally characterize both the spatial and 
temporal dynamics of chromatin states. On average, ~1.2% of the genome differs in chromatin state 
between tissues at the same stage (mean 1.2%, 31.3Mb; range 1.0%-4.0%, 26.8Mb-109.1Mb), but that 
percentage jumps to 17.2% if we discard the portion of the genome that shows no chromatin signal 
across all tissue-stages (i.e. constitutive state 15). Enhancer states show the highest degree of 
variability between tissues, reinforcing the role of enhancers in defining tissue and cell identity 
(Extended data figure 7a). Indeed, hierarchical clustering of our samples based on strong enhancer 
predictions alone (i.e. state 5) leads to clear separation by tissue, and captures relationships between 
tissues with similar developmental origin (Extended data figure 7b-d). Interestingly, this analysis 
revealed a strong relationship between limb and facial tissue, which was also observed in clustering 
results based on single histone modifications (Figure 2a-b). These findings are suggestive of a deep 
similarity in gene regulatory programs between these two tissues, and provide further support for the 
hypothesis of a common developmental origin for facial structures and limbs45,46. Within a given tissue, 
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we find that on average ~1.3% of the genome differs in chromatin state between adjacent 
developmental stages (mean 1.3%, 36.6Mb; range 0.03%-3.01%, 9.4MB-82.1Mb). While the fraction of 
the genome that differs in state between adjacent stages is roughly the same as the fraction that differs 
between tissues at the same stage, differences between stages are more subtle, as they are less likely 
to affect states characteristic of strong enhancers, promoters, or heterochromatin (States 5, 1, and 13, 
respectively; Extended data figure 7e). Nonetheless, these temporal changes capture important 
developmental processes like the maturation of Alveolar Type I cells (marked by Aqp527) just prior to 
the onset of pulmonary gas exchange at birth (Figure 3e), and the transition of predominant liver 
function from hematopoiesis in the early embryo to metabolism in the later stages of development47 
(Extended data figure 7f). A global summary of temporal changes in chromatin state reveals the 
tendencies of certain states to transition to others, including shifts from poised to active enhancers, 
bivalent to active promoters, and permissive to repressed chromatin (Figure 4c, Extended data figure 
7g).  
 To gain further insight into the dynamic processes occurring in each tissue, we focused 
specifically on the subset of enhancers that show dynamic activity across stages (referred to as 
“dynamic enhancers” below). To identify dynamic enhancers, we began by compiling lists of putative 
enhancers in each tissue (i.e. chromatin state 5). Next, we calculated a stage-specific activity score for 
each enhancer based on its level of H3K27ac enrichment, and used these activity scores to identify 
enhancers that change activity from stage-to-stage48 (see methods). Within each tissue, clustering of 
these dynamic enhancers revealed several predominant temporal patterns of activity (Extended Data 
figure 8). Considering forebrain as an example, we found four predominant patterns of temporal activity, 
which reflect underlying developmental processes (Figure 4d-g). Enhancers that peak in activity early in 
development are associated with GO terms related to general CNS and brain development (Figure 4d, 
cluster A), while enhancers that peak in middle stages are associated more specifically with 
neurogenesis and gliogenesis (Figure 4d, clusters B-C), and enhancers peaking latest in the 
developmental series are associated with synaptic function (Figure 4d, cluster D). By comparing the TF 
binding motifs enriched in each cluster to the expression levels of TF genes that target these motifs, we 
identified specific TFs that likely regulate the biological processes revealed by GO analysis. Consistent 
with published reports, these data suggest key roles for Sox2 in early brain development49,50, NeuroD6 
in neurogenesis during mid-late gestration51, and Mef2c in synapse formation52. Notably, the human 
orthologs of Mef2c and Sox2 are Mendelian disease genes linked to congenital defects of the CNS 
(MIM # 613443 and #206900, respectively). Similar catalogs for each tissue are available in Extended 
data figure 8 and Table S1, including dynamic enhancer clusters, corresponding GO terms, and 
enriched TFs.  
 
Linking Enhancers to Target Genes and Phenotypes 
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  Predicting the target genes of enhancers remains a major challenge in the field, in part because 
enhancers can be located hundreds of kilobases away from the genes they regulate22,23. To address 
this challenge, we developed a map of predicted enhancer target genes based on the correlation 
between gene expression (as measured by RNA-seq) and H3K27ac enrichment at TSS-distal 
enhancers within the same Topologically-Associating Domain (TAD) (Figure 5a; Extended data figure 
9a-b; Table S2). TADs have been shown to constrain the activity of enhancers to the genes in the same 
domain36,37,53. We assigned enhancers to target genes within the same TAD based on Spearman's rank 
Correlation Coefficient (SCC) between H3K27ac enrichment and mRNA expression across all 66 
tissue-stages (Extended data figure 9a) (p-value <= 0.05  and SCC >= 0.25; see methods). We took 
advantage of biological replicates for both the chromatin and RNA-seq data to derive independent 
target gene maps for each replicate. These maps include 31,965 and 32,735 enhancer-gene 
assignments, respectively, with an overlap 21,142 (Extended data figure 9c-e). Overall, these target 
gene maps are highly reproducible (SCC = 0.71 between replicates, evaluated as the number of 
enhancers per gene). Interestingly, we found that genes with 5 or more assigned enhancers are 
associated with biological processes related to development and differentiation, whereas genes with 
only a single assigned enhancer tend to be involved in cellular and metabolic processes more 
consistent with “housekeeping” functions (Extended data figure 9f). This result further highlights the 
importance of enhancers in directing the expression of developmental genes. 
 To further evaluate the accuracy of our enhancer target gene maps, we made use of published 
data from chromatin conformation capture technologies54-56, which assay physical interactions between 
promoters and enhancers. We found that our correlation-based map predicts experimentally 
determined enhancer-gene interactions with higher accuracy than assigning an enhancer to the nearest 
adjacent gene (Figure 5b; Extended data figure 9g). We also sought to determine whether our map of 
enhancer target genes in mouse could be useful for predicting human enhancer-gene interactions. To 
this end, we identified human orthologs of the enhancers and genes in our mouse map, and used data 
from the GTEx project to assess whether the enhancer-gene relationships inferred in mouse are likely 
to be conserved in human. The GTEx project has identified a large collection of human expression 
quantitative trait loci (eQTLs)57, which are known to be enriched in enhancers and other regulatory 
elements58. Importantly, each eQTL is connected to a target gene by genetic association. Thus, we 
hypothesized that if the enhancer target genes we predict in mouse are applicable to human, we should 
see an enrichment for eQTLs that link the human orthologs of these enhancers to the same target 
genes by genetic association. Indeed, across a variety of human tissues we see a significant 
enrichment of eQTLs that support our enhancer target gene predictions (Figure 5c).  
 With this set of enhancer target gene predictions in hand, we again focused on the subset of 
genes known to cause Mendelian disease when mutated (“OMIM genes”)35. Mendelian diseases are 
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predominantly caused by highly penetrant mutations that often effect coding sequence59. In contrast, 
SNPs associated with lower-penetrance non-Mendelian phenotypes by Genome-Wide Association 
Studies (GWAS) are highly enriched in putative regulatory sequences60. This suggests that 
dysregulation of gene expression is a common mechanism contributing to non-Mendelian phenotypes, 
which include diseases with enormous human health burden like coronary heart disease61 and Type 2 
diabetes62. We hypothesized that if enhancers which regulate Mendelian disease genes are disrupted 
by common sequence variants (i.e. SNPs), it might lead to less penetrant non-Mendelian phenotypes. 
To explore this hypothesis, we examined the frequency of GWAS SNPs (i.e. SNPs associated with a 
human phenotype by GWAS) in enhancers linked to OMIM genes by our correlative map, and 
compared this with the frequency of GWAS SNPs in enhancers linked to non-OMIM genes. Indeed, we 
find a highly significant enrichment for GWAS SNPs in enhancers linked to OMIM genes (p=4.3e-8, chi-
squared test). We also compared enhancers linked to OMIM genes with enhancers in the same TADs 
that are not linked to OMIM genes. Again, we see a significant enrichment for GWAS SNPs in the 
enhancers linked to OMIM genes (p=7.29e-4, chi-squared test; Extended data figure 9h; 
Supplementary Table S4). These results points to a systematic relationship between highly penetrant 
mutations that lead to Mendelian disease, and lower penetrance enhancer variants that may impact the 
regulation of those same genes and lead to more common phenotypes. For example, in Figure 5d we 
highlight Bcl11a. Coding mutations in the human ortholog (BCL11A) cause Dias-Logan syndrome 
(MIM# 617101) – also known as “Intellectual developmental disorder with hereditary persistence of fetal 
hemoglobin.” The Bcl11a locus contains two large clusters of putative enhancers that are active in the 
CNS and embryonic liver (a site of erythropoiesis), respectively. Indeed, the human ortholog of the liver 
enhancer cluster has been extensively characterized in human blood lineages63,64, and a human 
sequence orthologous to the CNS enhancer cluster has been validated in vivo65. Interestingly, the 
human liver enhancer ortholog contains nine total GWAS associations, eight of which are related to 
hemoglobin levels (the 9th association is to schizophrenia). In contrast, the CNS enhancer orthologs 
contains three GWAS associations, all with phenotypes related to neurodevelopment or cognitive 
function (Attention deficit hyperactivity disorder, Educational attainment). These observations suggest 
that while Bcl11a coding mutations lead to a pleiotropic syndrome with manifestations in both the CNS 
and hematopoietic systems, non-coding regulatory variants at the same locus may lead to non-
syndromic phenotypes that predominantly effect one system or the other, depending on which 
enhancer is affected. 
 
Relationship between H3K27ac enrichment and enhancer validation rate.  
 
 In several of the analyses described above, we have used chromatin state to study putative 
enhancers. Chromatin states (and even H3K27ac alone) have proven to be effective tools for 
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identifying enhancers14,48,66,67, but the accuracy of these methods remains under investigation. The 
putative enhancers identified in this study are supported by multiple lines of evidence including the GO 
and motif enrichments discussed above (Figure 4f) as well as tissue-specific enrichments for in vivo 
validated enhancers from the VISTA database65 (Extended data figure 10a). Anecdotally, we have 
noted that putative enhancers with stronger H3K27ac enrichment are more likely to validate in 
transgenic mouse reporter assays, which is an important consideration because the level of H3K27ac 
enrichment at putative enhancers can vary by orders of magnitude within a single tissue or cell type. To 
more systematically examine this relationship between H3K27ac enrichment level and validation rate, 
we used transgenic mouse assays68 in E12.5 embryos to test 150 enhancers predicted from E12.5 
forebrain, heart, or limb tissue that fell into one of three H3K27ac enrichment rank categories: high 
(selected from ranks 1-85), medium (ranks 1500-1550), or low (ranks 3000-3050) (Figure 6, Extended 
data figure 10b, Supplementary Table S5). We found that ~60% of the high-ranking enhancers 
displayed reproducible reporter gene expression in the expected tissue. However, <30% of predicted 
enhancers from the two lower-rank groups validated (Figure 5a, p-values < 0.01, Fisher’s exact test). 
These results are consistent with a similar validation of enhancers predicted from e11.5 tissues 
(ENCODE Consortium, in preparation). In addition, high-ranking enhancers that validated in the 
expected tissue were also more likely to have enhancer activity in additional tissues (Figure 6b, p-
values < 0.05, Mann-Whitney U Test). Importantly, no significant differences were observed in 
reproducibility rates (i.e. the percentage of embryos with reproducible activity) between rank classes 
(Extended data figure 10c).  Overall, these results demonstrate that loci with stronger H3K27ac 
enrichment are more likely to direct reporter expression in the expected tissue, and tend to direct 
reporter expression in a wider variety of tissues.  
 The results of these transgenic reporter assays provide an intriguing perspective on one of the 
most important questions in the field: what portion of sequences marked by an enhancer chromatin 
signature truly function as enhancers in vivo? Surveys of chromatin state and chromatin accessibility in 
a single tissue or cell type often predict enhancers numbering in the tens or even hundreds of 
thousands. In the past this has led us and others to estimate the total number of enhancers in the 
genome at several hundred thousand or more66,69. In contrast, the results of our transgenic assays 
suggest that outside of the top enhancers in a given tissue (as ranked by H3K27ac enrichment), the 
validation rate in this assay drops to roughly one-third. In light of these results, we think it is important to 
approach estimates of enhancer abundance with a healthy degree of caution, but we do not think these 
estimates should be abandoned entirely as they likely provide a reasonable upper bound estimate for 
the number enhancers in the genome. Although our data clearly suggests that the true positive rate of 
chromatin-based enhancer predictions decreases as function of H3K27ac level, it is difficult to 
determine exactly what this true positive rate is. Definitive proof of an enhancer’s function (or lack 
thereof) requires genetic manipulation of that enhancer in its native context, followed by extensive 
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measurements of the resulting impact on gene expression70-72. Even such rigorous genetic experiments 
can be difficult to interpret, because an enhancer’s function might be limited to a very specific set of 
conditions that are difficult to identify and/or reproduce in an experimental setting. In addition, one 
enhancer may compensate for the loss of another, achieving a redundancy that could serve to make 
regulatory programs more robust to perturbations. Ultimately, we think our results highlight the 
importance of continued investigation into the molecular basis of enhancer function, and encourage the 
continual assessment of global enhancer estimates as new data points like those reported here 
become available. 
 
 In summary, we present a survey of the chromatin landscape in the developing mouse embryo 
that is unprecedented in is breadth. Our results describe a multi-tiered compendium of functional 
annotations for the developmental mouse genome, yielding valuable insight into key developmental 
processes and regulatory factors. The resources generated here include chromatin state maps for each 
tissue and stage, catalogs of enhancers that show dynamic activity during development, a genome-
wide map of predicted enhancer target genes, and a collection of transgenic reporter assays that 
demonstrates a strong relationship between H3K27ac signal and likelihood of validation. We further 
reveal an important role for Polycomb-mediated repression in regulating TF genes during development, 
and a systematic connection between Mendelian diseases and complex common diseases likely 
caused by perturbation of the same genes. Due to the uniquely critical role of the mouse in biomedical 
research, we believe that the tools and insights developed here will prove to be a valuable resource to 
the biomedical research community. 
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MAIN FIGURE LEGENDS 
 
Figure 1: Profiling histone modifications during mouse embryonic development. (a) Overview of 
the experimental design. (b) Characteristic patterns of histone modifications at different types of gene 
loci: Neurod2 (chr11:98,318,134-98,336,928; mm10), Rpl5 (chr5:107,895,370-107,914,164; mm10), 
Hoxa (chr6:52,199,870-52,218,665; mm10). Data shown are from forebrain at E15.5. (c) Tissue-
restricted H3K27ac enrichment at tissue-restricted regulators Neurod2 and Nkx2-5 (chr17:26,832,795-
26,855,694; mm10). Data shown from 12 tissues at stage E15.5. (d) Stage-restricted histone 
modification patterns at developmentally regulated loci Neurod2 and Myh6/Myh7 (chr14:54,927,121-
55,010,762; mm10). Note the switch in activity from Myh7 to Myh6 at P0. 
 
Figure 2: The histone modification landscape changes progressively during development and 
reflects developmental relationships between tissues. (a) k-means clustering of H3K27ac peaks 
based on normalized H3K27ac enrichment (see methods for details of normalization; k=8). Total 
number of H3K27ac peaks = 333,097. Numbers of elements in each cluster from top to bottom: 20497, 
50790, 31043, 36849, 38670, 31168, 36822, 87258. Tissue abbreviations same as figure 1. (b) 
Dendrograms from hierarchical clustering based on signal for each histone modification, as indicated. 
Note the consistent relationships between tissues of similar developmental origin. (c) Progressive 
changes in histone modifications shown by pearson correlations of peak strength between replicates 
that are either from the same stage (i.e. developmental stages separating datasets = 0), or from 
different stages (separated by 1 - 6 intervening stages, as indicated). (d) Pearson correlation 
coefficients between all Heart H3K27ac datasets from E11.5 to P0. 
 
Figure 3: A 15 state model characterizes the mouse developmental chromatin landscape. (a) 
Overview of 15-state chromHMM model. A description is provided for each one of the 15 states. The 
states are grouped into four main categories: promoter, enhancer, transcription, heterochromatin. (b) 
Enrichment of chromatin states relative to annotated genes. The locations of these features were not 
considered when building the chromatin state model. (c) Chromatin state landscape at Gata4, a TF 
involved in heart development (chr14:63,181,234-63,288,624; mm10). (d) Chromatin state landscape at 
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Nkx2-1, a TF involved in lung development (chr12:56,507,647-56,560,509; mm10). (e) Chromatin state 
landscape at Aqp5, a marker of mature Alveolar Type 1 cells in the lung, which is expressed just prior 
to birth (chr15:99,589,794-99,596,121; mm10). P0 lung stage indicated by black arrowhead. 
 
Figure 4: Repression and activation of cis-regulatory elements during development. (a) 
Enrichment of “molecular function” GO terms in genes near repressed regions (state 13). GO terms on 
the y-axis are ordered by average enrichment p-value across all tissues and stages (most significant on 
top to least significant on the bottom). The top 20 GO terms are listed on the right, and are all related to 
TF function. (b) The relative frequency of repressive chromatin (state 13) at four different sets of TSS: 
1) all GENCODE protein coding TSS (N=90,384), 2) the subset of (1) that belong to transcripts of TF 
genes (N=1,019), 3) the subset of (2) that are also known to cause to Mendelian phenotypes when 
mutated (i.e. “OMIM” genes; N=227), 4) the remaining OMIM gene TSS that do not encode TFs 
(N=3,497). The individual gene symbols indicate genes that are known to cause congenital defects 
when abnormally expressed. Not shown: TSS repressed in none of the 66 tissue-stages (77%, 62%, 
51%, and 74%, respectively), and TSS repressed in all 66 tissue stages (<1%, 2%, 3%, and <1%, 
respectively). (c) Sankey diagram showing the origin and fate of all genomic intervals classified as TSS-
distal strong enhancers (state #5) in E14.5 forebrain. The chromatin state classification of these regions 
was tracked across the available developmental stages, and the relative genomic coverage of each 
chromatin state at each transition is plotted. The thickness of each color (i.e. y axis) indicates the 
coverage of each state. (d) K-means clustering of dynamic enhancers based on H3K27ac signal at 
stages: E11.5, E12.5, e13.4, E14.5, E15.5, E16.5, P0. (e) Top 4 Biological Processes GO terms 
enriched in each cluster of dynamic enhancers in (d) as determined by GREAT. (f) Top 4 sequence 
motifs enriched in each cluster of dynamic enhancers in (d). Some motifs are abbreviated with “…” to fit 
in the panel. The full motifs are (top to bottom): POU domain factors TATGCAAAT; Nuclear Factor 1 
TTGGCTATATGCCAA; POU domain factors TAATTAATTA; MEF-related factors CTAAAAATAG; 
TALE-type home domain AGCTGTCAA. (g) Gene expression shown for TFs in the structural 
subfamilies that match motifs in (f) indicated by closed black circles.  
 
Figure 5: Maps of enhancer target gene prediction in mouse and human. (a) Genome browser 
view showing chromatin states at the Ascl1 locus (chr10:87,301,848-87,515,210; mm10). Color scheme 
is the same is in Figure 4. Black bars on top represent enhancers predicted to target Ascl1. Two of 
these enhancers have human orthologs (below main panel) that have been previously validates using 
in vivo transgenic reporter assays in mouse. Tissues with reproducible enhancer activity are indicated 
with arrow heads. (b) Enhancer-gene interactions identified by this correlative approach are generally 
more likely to be supported by chromatin interaction data than associations derived by a nearest gene 
approach. Chromatin interaction data from (Andrey et al., 2017) (upper box), (DeMare et al., 2013) 
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(middle box) and (Schoenfelder et al., 2015) (lower box). Note that the Liver capture Hi-C dataset 
contains ~600,000 interactions (or roughly 30 per TSS considering ~22K TSS in the genome). This is 
far more interactions than that Capture C or ChIA-PET datasets, which we expect may explain why the 
nearest gene assumption outperforms our predictions in this dataset alone. (c) The correlative 
enhancer-gene interactions are significantly enriched for human eQTL-gene associations (see 
Methods). *** p <= 0.001; ** 0.001 < p <= 0.01;* 0.01 < p <= 0.05; (Fisher’s Exact Test). (d) Genome 
browser view showing chromatin states at the Bcl11a locus (chr11:24,044,043-24,197,927; mm10). 
Boxes outline enhancer clusters active in the CNS (left) and liver (right). The subpanels below show 
regions of the human genome corresponding to the CNS enhancer cluster (chr2:60,752,530-
60,767,198; hg19) and liver enhancer cluster (chr2:60,711,940-60,741,118; hg19), respectively. The 
black bars on top represent the predicted Bcl11a enhancers from mouse, and green bars below 
represent GWAS SNPs for the EMBL-EBI GWAS catalog. SNP IDs lower left subpanel, from left to 
right: (rs2556378, rs2457660, rs356992). SNP IDs lower right panel, left to right: (rs4671393, 
rs11886868, rs766432, rs7599488, rs1427407). The black bar labeled hs967 shows a sequence 
previously tested in vivo. Reporter activity in E11.5 mouse embryo shown to the right. 
 
Figure 6: In vivo validation of predicted E12.5 enhancers.  We tested 150 total enhancers predicted 
from E12.5 forebrain, limb, or heart tissue using in vivo mouse transgenic assays. Predicted enhancers 
from each tissue were ranked, from strongest to weakest H3K27ac signal, and we selected elements 
for validation from three different rank categories (roughly ranks 1-85, 1500-1550, and 3000-3050). (a) 
Bars indicate the proportion of enhancers in each category that showed reproducible reporter staining 
in the expected tissue (blue) or any tissue (white). High ranking predicted enhancers had a higher 
validation rate in the correct tissue than lower ranking enhancers (p-values by 1-tailed Fisher’s exact 
test). (b) For those enhancers that validated in the expected tissue, the distribution of tissues with 
reproducible reporter gene expression for each enhancer by rank class is shown with violin plots.  High 
ranking enhancers showed reproducible activity in more tissues than those with lower ranks (p-values 
by one-tailed Mann-Whitney U Test). (c) Examples of enhancers from each tissue type and rank class 
that validated in the expected tissue.  Representative transgenic E12.5 embryos showing reporter 
expression (blue staining) are shown, along with the unique VISTA Enhancer Browser (PMID: 
17130149) identifier (mm number) and the enhancer’s reproducibility.  Images on the far right show a 
magnified image of the heart (RA, right atrium; LA, left atrium; RV, right ventricle; LV, left ventricle).  
Red arrowheads indicate the enhancer activity pattern in the forebrain, limb, or heart. 
 
METHODS 
 
Tissue Collection. All animal work was reviewed and approved by the Lawrence Berkeley National 
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Laboratory Animal Welfare and Research Committee. Tissue collection for all developmental stages 
was performed using C57BL/6N strain Mus musculus animals. For E14.5 and P0, breeding animals 
were purchased from both Charles River Laboratories (C57BL/6NCrl strain) and Taconic Biosciences 
(C57BL/6NTac strain). For all remaining developmental stages, breeding animals were purchased 
exclusively from Charles River Laboratories (C57BL/6NCrl strain). Wild-type male and female mice 
were mated using a standard timed breeding strategy. Embryos and P0 pups were collected for 
dissection using approved institutional protocols. Embryos were excluded if they were not the expected 
developmental stage. To avoid sample degradation, only one embryonic litter or P0 pup was processed 
at a time, and tissue was kept ice cold during dissection. Collection tubes for each tissue type were 
placed in a dry ice ethanol bath so that tissue samples could be flash frozen immediately upon 
dissection. Tissue from multiple embryos was pooled together in the same collection tube, and at least 
two separate collection tubes were collected for each tissue-stage for biological replication. Tissue was 
stored in a -80oC freezer or on dry ice until further processing. A step-by-step protocol for tissue 
collection, including detailed information about how embryonic stage was determined, can be found on 
the ENCODE Project website at https://www.encodeproject.org/documents/631aa21c-8e48-467e-8cac-
d40c875b3913/@@download/attachment/StandardTissueExcisionProtocol_02132017.pdf.     
 
ChIP-seq data generation. ChIP-seq experiments for all marks and tissues from E11.5 – P0 were 
performed as previously described66. The ChIP-seq protocol was modified slightly for all E10.5 
experiments due to the low amount of input (“micro” ChIP-seq). Detailed protocols for both standard 
and micro ChIP-seq including antibodies used and antibodies validations performed are available at 
www.encodedcc.org associated with each experiment described here. They can also be found at the 
links below. Standard ChIP-seq, Tissue fixation & sonication: 
https://www.encodeproject.org/documents/3125496b-c833-4414-bf5f-
84dd633eb30d/@@download/attachment/Ren_Tissue_Fixation_and_Sonication_v060614.pdf, 
Immunoprecipitation: https://www.encodeproject.org/documents/89795b31-e65a-42ca-9d7b-
d75196f6f4b3/@@download/attachment/Ren%20Lab%20ENCODE%20Chromatin%20Immunoprecipit
ation%20Protocol_V2.pdf, Library preparation: https://www.encodeproject.org/documents/4f73fbc3-
956e-47ae-aa2d-
41a7df552c81/@@download/attachment/Ren_ChIP_Library_Preparation_v060614.pdf. Micro-ChIP-
seq (E10.5), Tissue fixation & sonication: https://www.encodeproject.org/documents/1fcaab50-6ca0-
4778-88cb-
5f6b85170d21/@@download/attachment/Ren%20Lab%20ENCODE%20Tissue%20Fixation%20and%
20Sonication%20Protocol%20MicroChIP.pdf, Immunoprecipitation & Library preparation:  
https://www.encodeproject.org/documents/18580e80-0907-4258-a412-
46bcc37bd040/@@download/attachment/Ren%20Lab%20ENCODE%20Chromatin%20Immunoprecipi
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tation%20Protocol%20MicroChIP.pdf.  
 
ChIP-seq data processing. Histone ChIP-seq data were analyzed using a software pipeline 
implemented by the ENCODE Data Coordinating Center (DCC) for the ENCODE Consortium. A 
schematic representation of the pipeline is shown in Extended figure 10. Each step of the pipeline 
corresponds to a script written in the Python programming language that assembles the input files, runs 
external programs (such as the MACS2 peak caller), and calculates quality-control metrics. The 
methodology is similar to that previously described for ENCODE73 with the following modifications: The 
mapping step used bwa version 0.7.10 and samtools version 1.0, and MACS2 version 2.1.0 was used 
for signal track generation and peak calling. In order to ensure an adequate sampling of noise for 
subsequent replicate comparisons, peaks were initially called at a relaxed p-value threshold of 1 x 10-2.  
Such relaxed peak sets were generated for each biological replicate, for the replicates pooled, and for 
pooled pseudoreplicates of each true replicate (each pseudoreplicate consists of half the reads 
sampled without replacement). Peaks from the pooled replicate set were retained in the replicated peak 
set if they overlapped by at least half their length (in bases) peaks from both biological replicates.  
Additionally, peaks that overlapped both pooled pseudoreplicates were added to the replicated peak 
set.  In this way very strong biological replicates could “rescue” peaks that were only marginal in a 
second replicate. The pipeline is available to be run on the DNAnexus (https://www.dnanexus.com/) 
web platform, backed by cloud computing from Amazon Web Services (AWS), and is the same pipeline 
used for the analysis of all ENCODE histone ChIP-seq experiments. The platform provides both an API 
for programmatic execution of the pipeline and a web-based interface for interactive execution of the 
same workflows. ENCODE DCC uses this approach to ensure that primary data from different labs 
within the Consortium are processed uniformly, and thus minimizing factors that could confound 
subsequent comparisons74. The ENCODE DCC analyzed the experiments in parallel and accessioned 
the results to the ENCODE Portal73 (https://www.encodeproject.org/).  
 
Code availability. The ENCODE histone ChIP-seq pipeline is among the collection of ENCODE 
Uniform Processing Pipelines that can be found here: https://platform.dnanexus.com/projects/featured. 
The code is open-source, and available here: https://github.com/ENCODE-DCC/chip-seq-pipeline. 
 
Analysis of individual histone ChIP-seq data. K means clustering. To facilitate clustering across all 
tissues and stages, one master H3K27ac peak list was generated by merging peaks across tissue-
stages. Each peak was then scored for H3K27ac ChIP-seq fold enrichment over input in each tissue-
stage using bigWigAverageOverBed, and these values were quantile normalized across tissue-stages 
to eliminate potential confounding effects of systematic biases in the distribution of signal between 
tissues and/or stages. These normalized values are represented by the blue-black-yellow color scale in 
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Figure 2a. One additional data processing step was performed prior to clustering: across each row, the 
values were converted to a unit vector in R (x / sqrt(sum(x^2)), to prevent enrichment level within 
tissue-stages from dominating the clusters, rather than enrichment level between tissue-stages. Note 
that these unit vector values were only used for clustering; the values plotted are the normalized 
H3K27ac enrichment values. K means clustering was performed in R with k = 8 and default 
parameters. Rows were ordered within each cluster based on mean normalized enrichment. 
Hierarchical clustering of tissue-stages. Normalized ChIP-seq fold enrichment values were 
calculated for each mark as described for H3K27ac in the preceding subsection (not including unit 
vector conversion). Hierarchical clustering was performed in R with default parameters. The resulting 
dendrograms are plotted in Figure 2b. Calculation of distance between stages. For each mark, we 
used Pearson correlation to compare the similarity between all datasets from the same tissue. We then 
categorized these correlations values based on how many stages separate the datasets being 
compared: 0 for true biological replicates from the same stage up to 7 for comparisons of E11.5 
datasets to P0 datasets. These correlations are plotted in Figure 2c. Principle Component Analysis 
(PCA). The whole genome was split into 1kb tiling bins. Average fold enrichment signals were 
calculated for each bin using the bigwigoverbed.sh script from the UCSC website. Bins that overlapped 
a merged peak by a minimal 20% (reciprocal) was denoted as peak-bin. The average fold enrichment 
signals from each peak-bin were quantile normalized within the tissue (not across the tissue). The 
signal strength for each peak was calculated as the sum of the signals of all bins overlapping that peak. 
Principal component analysis was performed on the peak signals for each histone mark with the R 
function “prcomp”. PC1, PC2 and PC3 values were plotted for each sample. Metagene profiles. To 
illustrate the characteristic enrichment patterns at active and silent genes, we used very conservative 
definitions to define these gene sets here. Active genes are defined as RPKM > 10 in every tissue-
stage evaluated here (see Table S6 for list of public RNA-seq datasets). Silent genes were defined as 
RPKM < 2 in all tissue-stages. Metagene profiles were plotted with deeptools plotProfile75, using data 
from E15.5 Heart. Correlation between replicates. To facilitate comparisons of peak strength 
between replicates, we began with a single list of peaks called for each tissue-stage using data pooled 
from both replicates. Then, we scored these peaks for ChIP-seq fold enrichment over input for each 
replicate separately using bigWigAvgOverBed, and performed quantile normalization to eliminate 
confounding effect of systematic biases in the distribution of signal between replicates. We then used 
Pearson Correlation to compare the replicated of each experiment. “Narrow” marks (H3K4me3, 
H3K4me2, H3K27ac, H3K9ac) for tighter peaks of enrichment and tend to correlate more strongly than 
“broad” marks (H3K27me3, H3K4me1, H3K9me3, H3K36me3). 
 
ChromHMM. Generating the model. Chromatin datasets (bam files) were downloaded from the 
ENCODE DCC on October 15, 2016. De-duplicated bam files for each sample, along with their 
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respective input controls, were binarized using the binarizeBam function of ChromHMM, with default 
parameters. Models considering 2 to 24 states were learned separately on the two replicates using the 
LearnModel function, with default parameters. For the rest of the analyses, we leveraged the availability 
of two, distinct time series; namely, we applied the same strategy separately and compared the results 
a posteriori. The conclusions obtained were invariably consistent, suggesting that the inferences on a 
single time series (at least in terms of global genomic patterns) are highly reproducible. Identifying the 
optimal number of chromatin states. We devised two different strategies to identify the minimal 
number of states that capture the combinations of histone modifications present in the data, both of 
which converged on a 15 state model. First, the ChromHMM CompareModels function was run 
separately on the two series. This function compares the emission parameters of a selected model to a 
set of models (in terms of Pearson’s correlation), and outputs the maximum correlation of each state in 
the selected model with its best matching state in each other model. We used this function to compare 
the “full” model (namely the one that consider 24 states) to the states in the simpler models. We then 
calculated the median correlation of all the 24 states against the simpler models, plotted these numbers 
against the number of states in the model and look at what number of states both series reached a 
plateau. As a complementary strategy, the emission probabilities from all the 23 models (considering 2 
to 24 states) from both replicates were clustered together. The rationale behind this strategy is that very 
similar states across models will tend to cluster together, so there must be an optimal number of 
clusters corresponding to the optimal number of states in the model. To this end, we applied k-means 
clustering with k between 2 and 24, and evaluated the goodness of the separation for each k as the 
ratio between the “Between sum of squares” (referred to as Between SS) and the “Total sum of 
squares” (Total SS). Very cohesive, well-separated clusters tend to approach a ratio of 1. Given a value 
of k, the ratio was averaged over one hundred realizations of the clustering. The ratio observed for k = 
24 was used as maximum, and the optimal number of states was then defined by the smallest value of 
k showing a ratio equal or higher than 95% of the maximum. Genome segmentation and chromatin 
state tracking across genomic positions. The segmentation was run separately for each sample, 
using the MakeSegmentation function of ChromHMM (default parameters) and the model derived from 
the first replicate. For the final set of replicated state calls we required that a region was assigned to the 
same state in both biological replicates (within a given tissue & stage). Regions that were not assigned 
to the same state in both replicates were re classified as “No Reproducible Signal” (distinct from state 
15 – no signal in both replicates). The unionbedg functionality of BEDTools76 v2.17.0 was exploited to 
keep track of the chromatin state of genomic intervals across a defined set of samples. Chromatin 
state trajectories along developmental time. Given a replicate for a defined tissue, all those genomic 
intervals classified in a specified state (e.g. #5, strong enhancers) in one or more time points were 
tracked using the approach described above. Considering each pair of adjacent developmental time 
points, the genomic coverage of each transition between each pair of states was then calculated. The 
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resulting numbers were then normalized on the coverage of the largest transition in the time series 
under investigation (e.g. liver, replicate #2) and shown as a directed graph. Clustering on enhancer 
states. After tracking the changes in chromatin state of each genomic base pair in the genome across 
multiple stages and tissues, the resulting matrix was binarized according to each segment being 
classified in a specified state (1) or any other state (0). The binary distances between all the pairs of 
samples considered in each specific analysis were then calculated. These were used either for 
comparisons or hierarchical clustering (Ward’s method). GO analysis. Functional enrichments through 
GREAT34 were obtained through the greatBatchQuery.py script. The resulting lists were first filtered for 
the relevant ontologies. After that, only the terms showing a binomial FDR <= 0.05 and a regional 
enrichment equal or higher than 2-fold were considered. WebGestalt77 was run with default parameters, 
specifically restricting the enrichment analysis to the GO Biological Process Ontology. VISTA validated 
elements were downloaded from https://enhancer.lbl.gov on June 17, 2016. Mm9 and hg19 coordinates 
were converted to mm10 using liftOver (setting -minMatch to 0.95 and 0.1, respectively). VISTA 
positive elements with any of the following annotations: "forebrain", "midbrain", "hindbrain", 
"neuraltube", "limb", "facialmesenchyme" or "heart" were considered for the following analysis. Liver 
was not considered in this enrichment analysis since there are currently <10 validated elements in 
VISTA showing reproducible staining in the liver. coverageBed from BEDTools v2.17.0 was used to 
calculate the coverage of the regions in each state in the E11.5 predictions with each tissue-specific 
group of VISTA elements. The fraction of bases covered was then normalized to the expected overlap, 
based on the overall genome-wide coverage of each state. The enrichment for repetitive elements was 
calculated using the OverlapEnrichment function of ChromHMM. Classification of TSS as active, 
repressed, OMIM, and/or TF. A 2kb window was defined around the TSS coordinates of all protein 
coding transcripts in GENCODE78 vM12. These 2kb windows (one per TSS) we overlapped with 
replicated chromHMM calls to determine their chromatin state in each tissue and stage. A TSS was 
classified as “active” in a given tissue-stage if this 2kb window overlapped the active promoter state 
(#1), and did not overlap any repressive states (#3, #13, #14). A TSS was classified as “repressed” in a 
given tissue-stage if this 2kb window overlapped a state characteristic of polycomb-mediated 
repression state (#3, #13), and did not overlap any active states (#1, #3, #4, #5, #6, #7, #10, #12). TSS 
that did not meet the criteria for either active or repressed in a given tissue-stage were left unclassified. 
Mouse orthologs of OMIM genes were taken directly from the “genemap.txt” available from 
www.omim.org, and filtered for genes with a “Disorder” type value of 3 – “the molecular basis of the 
disorder is known”. The full list of mouse TFs was downloaded from TFClass79. Ensembl Gene IDs 
were used to match GENCODE TSS to corresponding OMIM and TF genes. Characterization of 
dynamic enhancer elements. The temporal dynamic analysis was performed for each tissue 
separately. First, 1kb genomic bins that overlapped with regions defined as ChromHMM strong 
enhancer states in at least one stage were identified. Then we selected dynamic elements (bins) from 
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these strong enhancer bins using the bioconductor LIMMA package80. LIMMA is a package developed 
for calling differentially expressed genes for microarray but was also adapted for sequencing data with 
the LOOM functionality. LIMMA package was used to call differential binding between each adjacent 
stage comparisons (e.g. E11.5 vs E12.5, E12.5 vs E13.5, etc). P-values were calculated with the 
eBayes function within LIMMA with trend parameter disabled, and were adjusted using Benjamini-
Hochberg method. A bin was called overall dynamic if its adjusted p-value is less than 0.05 in any 
adjacent stage comparisons; otherwise it is called a non-dynamic bin. Non-dynamic bins were not 
included in the following analysis to reduce noise. We performed K-means clustering on dynamic bins 
across stages. The rows (bins) are normalized by dividing a common value so that the squares of the 
values sum up to 1. The optimal K was determined using the  “elbow method” to cut off at the K value 
where percentage of withinness values transition from increasing quickly to increasing steadily with 
larger K. The resulting heatmap of the K-means clusters were shown in Figure 4d and Extended data 
figure 8. For each of the identified clusters, we performed enrichment testing of “GO Biological 
Processes” using GREAT. Over-represented motifs for each dynamic cluster was identified with the 
following method: First, all vertebrate Motif position weight matrices (PWMs) were downloaded from 
JASPAR TF database and used to scan the peak-bins for motif occurrences with FIMO, MEME suite81. 
For each motif, we computed the odds ratio and the significance of enrichment in each cluster, 
comparing to non-dynamic bin pool using Fisher’s exact test. The non-dynamic bin pool were sampled 
with replacement to match the distribution of average signal strength from the dynamic bins. Following 
that, significant TF PWMs were grouped in subfamilies using the structural information from TFClass79 
because they share similar if not identical binding motifs. The top significantly over-represented TFs 
and their associated subfamilies were reported.  
 
A TAD-constrained map of enhancer-promoter associations. The reproducible strong enhancer calls 
(state #5) were merged using the mergeBed utility from BEDTools v2.17.0. After that, those regions or 
sub-regions overlapping the intervals +/- 2.5 kb from the TSS of genes in Gencode were excluded from 
the merged regions using subtractBed from BEDTools v2.17.0. Regions smaller than 2 kb were enlarged 
to 2 kb from their central coordinate (to allow for more robust signal estimation). This resulted in 66,556 
putative enhancers. H3K27ac signals at these regions were then quantified using uniquely aligned, de-
duplicated reads. These measurements were carried out by the coverageBed utility from BEDTools 
v2.17.0, then normalized to RPKM according to the sequencing depth of each sample, and log2-
transformed (zeros were replaced by the smallest detectable value larger than zero). The mRNA 
expression of protein-coding genes was tracked across the 66 samples. Small and non-coding RNAs 
were excluded from any subsequent step by considering only those genes with a Gencode biotype 
supporting protein-coding functionality. FPKM were log2-transformed (zeros were replaced by the 
smallest detectable value larger than zero). For each TAD defined in the genome of mouse ES-cells53, 
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the putative enhancers and genes were retrieved. All the enhancer-gene pairs within the TAD were then 
evaluated in terms of Spearman's rank correlation coefficient (SCC) between the H3K27ac pattern of 
enrichment and the mRNA expression across the samples. Each gene was assigned to the putative 
enhancer showing the highest value of SCC. In order to attach p-values to these correlations, a null 
distribution was estimated empirically, by calculating the SCC of the enhancer with all the genes on the 
chromosome. Two different strategies were employed to estimate a p-value: 1) a z-score was calculated 
by subtracting the mean and dividing by the standard deviation of the null. The corresponding p-value 
was then calculated using the pnorm function in R; 2) an empirical p-value was defined as the number of 
times an equal or better than the observed SCC was found in the null. Only those putative enhancers 
showing a p-value <= 0.05 (for both strategies) and a SCC >= 0.25 were retained. Two maps were 
independently derived from the two biological replicates. These respectively encompassed 31,965 and 
32,735 associations, with an overlap 21,142. Only these overlapping associations were used for further 
evaluation and analyses. Validation of the enhancer-gene map using published chromatin 
conformation data. Capture-C interaction data from the developing limb and brain54 were retrieved from 
the GEO (GSE84792). ChIA-PET interactions at sites bound by the cohesion subunit Smc1a in the 
developing limb55 were retrieved from the Supp. Table 2 of the original publication. Enhancer-gene 
contacts in fetal liver cells as inferred from Capture HiC56 were downloaded from ArrayExpress (E-MTAB-
2414). In all cases, mm9 coordinates were mapped to mm10 using liftOver. For each published dataset, 
only those regions in the enhancer-gene map overlapping any experimentally validated interaction were 
retained. The fraction of interactions showing experimental support was then calculated for both the gene 
assigned by correlation and the nearest RefSeq gene. Mapping of murine enhancer-gene map to 
human. The putative enhancer regions were mapped to the human genome (hg19) using liftOver, with 
a strategy similar to previous reports67. Each region was required to both uniquely map to hg19, and to 
uniquely map back to the original region in mm10, with the requirement that >=50% of the bases in each 
region were mapped back to mouse after being mapped to human. For each enhancer-gene pair, the 
orthologous human gene was inferred using BioMart82. The orthologous pairs were also required to share 
the same TAD in human (TADs derived from human ES-cells53). Validation of the enhancer-gene map 
using published eQTL-gene associations. Single-tissue eQTL-gene associations generated by the 
GTEx consortium83 were downloaded from the GTEx portal (http://gtexportal.org, release v6p). Only 
those tissues with more than 750k annotated eQTLs were considered. A control set of enhancer-gene 
associations matching the size and the TSS-distance distributions of the real enhancer-gene map was 
generated. Briefly, for each enhancer-gene pair, the distance between the TSS of the gene and the 
central coordinate of the enhancer was calculated; after that, a region of the same size of the enhancer 
centered at the same distance to the TSS of the gene but on the opposite side of the enhancer was 
picked as a control set. 
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Transgenic reporter assays. Names for functionally validated enhancers used throughout this work 
(mm numbers) are the unique identifiers from the VISTA Enhancer Browser (www.enhancer.lbl.gov)65. 
Enhancers were selected for testing as follows: The H3K27ac peak calls for three tissues (E12.5 heart, 
forebrain, and limb) were taken from the TSS-distal H3K27ac peaks called using the uniform 
processing pipeline (mm10-minimal) by the ENCODE Data Coordinating Center (narrow peaks from 
combined replicates).  Peaks for each tissue were ranked by enrichment score (most to least 
significant).  We then selected predicted enhancers from three different bins within each tissue’s ranked 
list for testing (bins were approximately ranks 1-85, 1500-1550, and 3000-3050).  Loci that were 
already included in the VISTA Enhancer Browser or that appeared to overlap unannotated promoters 
were excluded from testing.  In total, 150 predicted enhancers were tested, including 60 top ranked 
candidates (20 per tissue), 45 middle ranked (15 per tissue), and 45 lower ranked candidates (15 per 
tissue). Transgenic mouse assays were performed in FVB/NCrl strain Mus musculus animals (Charles 
River) as previously described68,84.  Briefly, predicted enhancers were PCR amplified and cloned into a 
plasmid upstream of a minimal Hsp68 promoter and a lacZ reporter gene.  Transgenic embryos were 
generated by pronuclear injection of the resulting plasmids into fertilized mouse eggs.  Embryos were 
implanted into surrogate mothers, collected at E12.5, and stained for β-galactosidase activity.  
Elements were scored as positive enhancers if at least three embryos had identical β-galactosidase 
staining in the same tissue.  Elements were scored as negative if no reproducible staining was 
observed and at least five embryos harboring a transgene insertion were obtained.  Genomic 
coordinates and results for each element are provided in Supplementary Table 5, through the ENCODE 
project data portal (www.encodeproject.org), and at the VISTA Enhancer Browser website 
(www.enhancer.lbl.gov). 
 
Mapping to repeat element families. Since ENCODE analysis pipeline were focusing on the uniquely 
mapped reads, a lot of information provided by the reads that are not uniquely mapped will be missed. 
This is especially undesirable for repetitive element analysis as there is a higher chance for read 
coming from a repetitive region of DNA will map un-uniquely to the reference genome. Hence, we use a 
new pipeline with two rounds of mapping steps to re-process all the fastq files. The pipeline utilizes all 
the reads for the purpose of gaining enough sensitivity to uncover the enrichment of any repetitive 
element subfamilies that were previously undiscovered because of low coverage. In the first round of 
mapping, sample reads were aligned to the reference genome mm10 using Bowtie1 with: bowtie hg19 -
p 16 -t -m 1 -S --chunkmbs 512 --max multimap.fastq input.fastq output.sam85. --max is used to 
separate reads mapping to multiple locations of the genome from uniquely mapped reads. 
In the second round of mapping, a customized assemblies file are constructed by concatenating 
genomic instances of each repetitive element subfamily, their 15 bp flanking genomic sequences and a 
200bp spacer sequence in FASTA format86. The annotation file for repetitive elements used in this step 
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was downloaded from Repeatmasker.org. A python script used with parameters are as following: 
python RepEnrich.py /data/mm10_repeatmasker.txt /data/sample_A sample_A 
/data/mm10_setup_folder sampleA_multimap.fastq sampleA_unique.bam --cpus 1687. The number of 
reads mapping to repetitive element subfamilies, repetitive element families, or repetitive element 
classes are determined using information from both uniquely mapped reads that overlap with repetitive 
element and un-uniquely mapped reads. Since some of the repetitive element subfamilies are very 
similar to each other, a fractional counts method was used to classify the reads that map to multiple 
repetitive element subfamilies. It sums reads mapping uniquely to a repetitive element subfamily once 
and counts reads mapping to multiple subfamilies using a fraction 1/Ns, where Ns = number of 
repetitive element subfamilies the read aligns with. A table of counts that estimate enrichment signal for 
the repeats classes across different tissues is built as the final output for plotting the figures. 
 
Data processing in R. Most of the described data processing steps (plotting, statistical tests, calculating 
correlations and hierarchical clustering) were performed in the statistical computing environment R 
v.3.3.1 (www.r-project.org). 
 
DATA ACCESS 
 
 Raw and processed ChIP-seq data reported here can be accessed via the ENCODE Data 
Collection and Coordiantion (DCC) website www.encodedcc.org. More specifically, a full list of the 
ChIP-seq experiments can be found here:  
https://www.encodeproject.org/search/?type=Experiment&assay_slims=DNA+binding&assay_title=ChI
P-seq&award.rfa=ENCODE3&lab.title=Bing+Ren%2C+UCSD&limit=all. ????????????????????
?????????????????????????????????????????????????????????????  
EXTENDED DATA FIGURE LEGENDS 
 
Extended data figure 1. Summary of primary ChIP-seq data. (a) Table summarizing the 
characteristic enrichment patterns for each histone modification surveyed here. Note that modifications 
are generally categorized as “narrow” or “broad” depending on the typical breadth of enrichment. 
H3K9me3 is further distinguished from other broad marks because it shows very few regions of 
enrichment in non-repetitive sequence in primary tissues and cells42. (b) Metagene profiles illustrating 
the typical patterns of histone modification enrichment at active genes (defined as RPKM > 10 in all 
tissue-stages surveyed here). ChIP-seq data plotted is from embryonic Heart at E13.5. (c) Sequencing 
depth is plotted for every library reported (N=1,128 ChIP + 168 input). ENCODE “usable” read depth 
standards (mapq>30, and after PCR duplicate removal) are indicated to the right. Note that read depth 
standards changed part way through our study: increasing from 10M to 20M for narrow marks, 20M to 
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45M for broad marks, and 10M to 30M for input. All narrow mark libraries exceed the 10M minimal 
depth. Broad mark libraries exceed the 20M minimal depth with only 4 exceptions, all of which exceed 
19M. Input libraries exceed the 10M minimal depth with only 1 exception, which exceed 9.7M. The read 
depth standard for H3K9me3 >45M mapped reads of any mapq (because most H3k9me3 is repetitive 
sequence, see Extended Figure 6); all H3K9me3 libraries exceed this threshold. (d) Mapping quality is 
plotted for every library, measured as the fraction of reads with mapping quality scores (mapq) > 30. 
Reads with lower mapq scores (i.e. non-uniquely mapping reads) were eliminated from downstream 
analysis. (e) Three metrics of library complexity are plotted (NRF, PBC1, PBC2). See ENCODE data 
standards88 for detailed descriptions and formulas. Tables below each plot show the percent of libraries 
that exceed the thresholds indicated. (f) Two measures of signal-to-noise ration are plotted (NSC, 
RSC). Again, detailed descriptions are available in the ENCODE data standards descriptions.  
 
Extended data figure 2. ChIP-seq peak calling. (a) Schematic representation of ChIP-seq peak 
calling pipeline. More information can be found here: https://www.encodeproject.org/chip-seq/. (b) Four 
different peak summary statistics are plotted for every tissue-stage. From top to bottom: 1) Number of 
peaks called (passing IDR threshold); 2) Total coverage of those peaks; 3) Peak coverage as in (2), but 
separated according to tissue; 4) Peak coverage as in (2), but separated by stage. Note that E10.5 
ChIP-seq experiments were performed with a modified protocol, and in some cases a different more 
sensitive antibody (H3K27ac, H3K4me1). We suspect that is why E10.5 sometimes appears as an 
outlier in terms of coverage. (c) Peak reproducibility as measured by the percentage of peaks called 
form the pooled data that were called independently in both individual replicates. (d) Peak 
reproducibility as measured by correlation of peak strengths (average bigwig signal within each peak) 
between independent replicates. (e) Principle Component Analysis of all tissue-stages based on the 
distribution of ChIP-seq signal across the genome.  
 
Extended data figure 3. Dynamic ChIP-seq signal across developmental space and time. (a) 
Genome browser view of Gad1 (chr2:70,547,104-70,615,401; mm10), a marker of GABAergic neurons, 
showing the gain of active chromatin signatures during forebrain development. (b-c) Genome browser 
views of Ccnb1 (chr13:100,776,802-100,788,423; mm10) and Cdk2 (chr10:128,693,493-128,709,497; 
mm10), key cell cycle regulators, showing the loss of active chromatin signatures during forebrain 
development. (d) multi-tiered plot showing the relationship between tissue-specificity, stage-specificity, 
and location relative to TSS. For each mark, peaks were merged across all tissue-stages. These 
merged peaks were then overlapped with each tissue-stage individually to determine how many 
individual tissues and stages that peak was called in. The x-axis at the top indicates how many tissues 
a given peak was called in (1 - 12). The top line graph shows the tissue-specificity of peaks, as the 
percentage of total peaks for a given mark that were called in 1 - 12 tissues. The middle heatmap 
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shows stage specificity, as the fraction of stages within a given tissue that a peak is called in. In other 
words, if a peak is called in 3 tissues, what fraction of the available stages within those 3 tissues was 
the peak called in. Note that peaks which are more restricted to specific tissues, are also more 
restricted to specific stages within those tissues. The bottom heatmap shows the location of peaks 
relative to TSS, as the fraction of peaks that overlap an annotated GENCODE TSS. Note that peaks 
which are more consistent across tissues and across stages are much more likely to overlap a TSS. (e) 
Heapmap showing the H3K27ac ChIP-seq signal at H3K27ac ChIP-seq peaks called in forebrain 
(merged across stages). Peaks are clustered based on how many stages within forebrain they were 
called in (y axis, left). The number of peaks in each cluster is indicated to the right. 
 
Extended data figure 4. 15-state chromHMM model. (a) Schematic representation of the chromatin 
states identification strategy applied in this study. (b) Heat maps showing the maximum correlation of 
each state in the “full” model (y-axis) with its best matching state in each simpler model (x-axis). The 
median correlation of all the 24 state is shown in the plots on top of the heat maps. (c) Plot showing the 
classification of the k-means clustering of the emission probabilities from all the models. The optimal 
number of states was defined by the smallest value of k showing a ratio equal or higher than 95% 
(orange line) of the maximum clusters’ separation (red line). SS = Sum of Squares. (d) Heat maps 
showing the emission probabilities for each chromatin mark in each state, as defined by ChromHMM, 
for both replicates. (e) Box plots showing the similarity between replicates, among samples from the 
same tissue and among all samples, considering either active TSS (state #1, red) or strong enhancers 
(state #5, orange). P-values from Mann-Whitney tests. Similarity measured as pairwise binary distance 
(see Methods). (f) Bar plot showing the enrichment of each mark in state 11 (permissive) relative to 
state 15 (no signal, genomic background). Note that the chromHMM emission probability for 
H3K36me3 in state 11 is >30-fold higher than genomic background. (g) Comparison of the ChromHMM 
model reported here with previously published chromHMM models. Grey vertical bars indicate histone 
modifications profiled here that were not included in those previous studies. Horizontal bars indicate 
chromatin states identified in our study that do not have a clear counterpart in those studies.  
 
Extended data figure 5. Chromatin states at developmental genes. (a) Genome browser views 
showing tissue-restricted activity patterns at Nkx2-5 (chr17:26,818,483-26,870,007), Cdx2 
(chr5:147,294,550-147,313,599), Barx1 (chr13:48,649,148-48,680,395), Wt1 (chr2:105,097,427-
105,200,306), and Foxg1 (chr12:49,362,757-49,416,342). Myc as shown in the far right as an example 
of a gene that is not tissue restricted across our developmental series (chr15:61,972,107-62,003,584). 
All coordinates are mm10. (b) Genome browser views showing stage-restricted activity patterns at 
NeuroD2 (chr11:98,308,801-98,345,075) and Gad1 (chr2:70,547,104-70,615,401). (c) This plot is a 
counterpart to Figure 4b. The relative frequency of active chromatin (State 1) at four different sets of 
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TSS: 1) all GENCODE protein coding TSS (N=90,384), 2) the subset of (1) that belong to transcripts of 
TF genes (N=1,019), 3) the subset of (2) that are also known to cause to Mendelian phenotypes when 
mutated (i.e. “OMIM” genes; N=227), 4) the remaining OMIM gene TSS that do not encode TFs 
(N=3,497). The individual gene symbols indicate genes that are known to cause congenital defects 
when abnormally expressed. Not shown: TSS active in none of the 66 tissue-stages (43%, 32 %, 33%, 
and 39%, respectively), and TSS active in all 66 tissue stages (14%, 19%, 15%, and 13 %, 
respectively). 
 
Extended data figure 6. H3K9me3 marked heterochromatin. (a) Genome browser view showing a 
large region of chromosome 15 (chr15:87,165,311-104,043,685; mm10). Signal tracks (fold enrichment 
over input) are shown for all marks. Note that H3K9me3 looks relatively flat, unlike the other marks. 
Note also that this signal does not include reads that map non-uniquely to the genome (i.e. map to 
repetitive elements, mapq<30). We find very few regions of strong H3K9me3 enrichment outside of 
repetitive elemetns, consistent with previous reports of H3K9me3 distribution in primary tissues42. (b) 
Bar chart showing the fraction of total sequencing reads that mapped to the reference genome (light 
green), and that mapped uniquely to the reference genome (mapq >= 30; dark green). Bar height 
represents the mean for all ChIP- libraries reported here separated by mark, and error bars represent 
standard deviation. Control bars represent ChIP input libraries (no IP step). Note that all marks and 
input have a high mapping rate (mean >90%).  However, H3K9me3 has a markedly low rate of unique 
mapping, suggesting that this modification is specifically enriched in non-unique (i.e. repetitive) 
genomic regions. (c) Stacked bar plots show the type of repetitive elements that the non-uniquely 
mapping reads from (b) correspond to (see methods). Note that H3K9me3 reads are highly enriched in 
satellite repeats relative to the input control samples. (d) Genome browser view of chromatin states 
showing that some Pchd (chr18:36,720,767-38,058,585; mm10) and Zfp (chr11:50,774,724-
50,939,391; mm10) genes do show significant H3K9me3 enrichment (state 14) during development. 3’ 
UTRs of Zfp genes marked by H3K9me3 (noted previously44) are indicated by pink arrow heads. (e) 
Similar to (d), but showing raw ChIP-seq fold enrichment tracks for each mark across these regions.  
 
Extended data figure 7. Dynamic chromatin states. (a) Heatmap shows the fraction of bases for 
each state in forebrain that are in a different state in other tissues at the same stage. The bar plot on 
the right shows the median value (fraction of variable bases) considering all tissues. Enhancer states, 
which are highlighted by a vertical bar, are the most variable between tissues. (b) Dendrogram showing 
the hierarchical relationships among strong enhancers (state #5) in different tissues during 
development (clustering according to binary distance, Ward’s method). (c) Same as (b) but considering 
only limb and face samples. (d) Heat map showing the statistical significance of the enriched functional 
terms (GO Biological Process, as assessed by GREAT, x axis) for the sets of strong enhancers (state 
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#5) across each tissue-stage (y axis). The terms were hierarchically clustered (average linkage) 
according to Pearson’s correlation. A subset of the terms highly enriched in both Limb and Face are 
listed below the main heatmap. (e) Heatmap shows the fraction of bases for each state in forebrain 
e11.5 that are in a different state at other time points. The bar plot on the right shows the median value 
(fraction of variable bases) considering all tissues. (f) Heat map showing the most enriched biological 
processes (GO terms) for the genes in the vicinity of liver enhancers. For each one of the indicated 
sets, the significantly enriched terms were identified and divided into deciles (based on statistical 
significance). The ten most enriched terms for each set were then grouped together and hierarchically 
clustered. Genes involved in either hematopoiesis or metabolic processes are color-coded as indicated. 
(g) Sankey diagram showing the tendencies of each chromatin state at a given stage (left, Stage N) to 
transition to other chromatin states at the following developmental stage (right, Stage N+1).  
 
Extended data figure 8. Dynamic enhancer patterns for 12 tissues. K-means clustering of dynamic 
enhancers in each tissue based on H3K27ac signal at available stage from E11.5 to P0. The number of 
clusters within each tissue, and the number of dynamic enhancers within each cluster, are indicated to 
the left of each heat map. Corresponding GO enrichment and motifs are provided in Table S1.  
 
Extended data figure 9. Predicting enhancer target genes. (a) Schematic of the approach to assign 
enhancers to target genes. Correlation between H3K27ac signal at putative enhancers (green bars) 
and mRNA expression of genes (black bars) in the same TAD across tissues and developmental time 
was used to infer the most likely enhancer-gene interactions. (b) Genome browser view showing 
chromatin states at the Ascl1 locus, as in Figure 5a, but showing ChIP-seq fold enrichment tracks 
instead of chromatin states. (c) (Upper panel) Plot showing the fraction of enhancer-gene associations 
common to the two replicates (Reproducibility) as a function of the stringency applied to the 
Spearman’s Correlation Coefficient (SCC). The two curves correspond to developmental time series. 
(Lower panel) Scatterplots showing the relation between the number of putative enhancers per gene at 
the default cutoff (SCC = 0.25, x-axis) vs a more stringent cutoff (SCC = 0.45 or 0.75, respectively, y-
axis). (d) Scatterplot showing a comparison of the number of putative enhancers per gene in the two 
replicates. (e) Histogram showing the distribution of the number of enhancers per gene. (f) The most 
significantly enriched GO terms are listed for genes that have one predicted enhancer (top) and genes 
with >= 5 predicted enhancer (bottom). (g) As in Figure 5b, this plot shows that enhancer-gene 
interactions identified by this correlative approach are generally more likely to be supported by 
chromatin interaction data than associations derived by a nearest gene approach. To ensure that this 
was not due to an artifact of the chromatin capture technologies being unable to detect very short range 
interactions, we used different distance cutoffs (10Kb, 100Kb) to define the “nearest” non-target gene. 
(h) Bar plot show the frequency of GWAS hits (EMBL-EBI catalog) in three different types of enhancers: 
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enhancers predicted to target OMIM genes (top); enhancers predicted to target genes other than OMIM 
genes (middle); enhancers in the same TADs as OMIM genes, but not predicted to target those OMIM 
genes (bottom).  
 
Extended data figure 10. Transgenic validation results for predicted enhancers. (a) Heat map 
showing the tissue-specific enrichments of VISTA enhancers for the different chromatin states in E11.5 
heart, limb and forebrain. (b) Representative e12.5 transgenic embryos for each of the 61 enhancers 
that validated in the expected tissue (forebrain, limb, or heart). Reporter gene expression is indicated 
by blue staining, and enhancer names (mm numbers) are the unique identifiers from the VISTA 
Enhancer Browser65. Red arrows indicate the position of the forebrain, limbs, or heart.  See also 
Supplementary Table 5 for results. (c) Violin plots showing transgenic enhancer assay reproducibility 
for different rank classes of tested elements.  Only those enhancers that validated in the correct 
expected tissue are shown. Reproducibility differences between rank classes were not statistically 
significant (Mann-Whitney U Test). 
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